Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Trial of Vandetanib (ZD6474, Zactima) and Fulvestrant (Faslodex) as Third-Line Treatment of Advanced Non-Small Cell Lung Cancer

NCT01004419 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.

NCT NCT01004419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01004419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Trial of Vandetanib (ZD6474, Zactima) and Fulvestrant (Faslodex) as Third-Line Treatment of Advanced Non-Small Cell Lung Cancer
Lead sponsor
University of Wisconsin, Madison
Phase
Phase 1
Overall status
Withdrawn
Start date
November 30, 2009
Completion date
May 31, 2011
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non small cell lung